We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Abaloparatideis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Abaloparatide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2016–2025 with a typical study size of 982 participants.
Based on 11 studies · 3 meta-analyses · 5 RCTs · 4,835 total participants
Confidence
HighBy outcome
Abaloparatide has an evidence score of 6/10 — moderate evidence based on 11 indexed studies, including 3 meta-analyses. A prescription anabolic (bone-building) osteoporosis drug — the medicine Tymlos — a synthetic analog of parathyroid-hormone-related peptide PTHrP(1-34), FDA-approved in 2017 for postmenopausal women at high fracture risk and later for men. Honest appraisal: unlike most peptides sold online, this one has a REAL pivotal phase-3 fracture RCT (ACTIVE) plus a sequential-therapy extension (ACTIVExtend) and several network meta-analyses — strong evidence for its narrow osteoporosis indication, with a slightly smaller trial base than its older sibling teriparatide. It is a daily subcutaneous injectable prescription drug, not a dietary supplement. It raises bone density and cuts vertebral and nonvertebral fracture risk, but it carries a HISTORICAL rat-based osteosarcoma signal (the boxed warning and 2-year cumulative-use limit were REMOVED by the FDA in 2020-2021), causes hypercalcemia (less than teriparatide) and orthostatic dizziness, and must be obtained and supervised by a prescriber. Representative study: PMID 37130601.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Last reviewed June 2026 · evidence from 11 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Abaloparatide (Tymlos; synthetic PTHrP(1-34) analog)
A prescription anabolic (bone-building) osteoporosis drug — the medicine Tymlos — a synthetic analog of parathyroid-hormone-related peptide PTHrP(1-34), FDA-approved in 2017 for postmenopausal women at high fracture risk and later for men. Honest appraisal: unlike most peptides sold online, this one has a REAL pivotal phase-3 fracture RCT (ACTIVE) plus a sequential-therapy extension (ACTIVExtend) and several network meta-analyses — strong evidence for its narrow osteoporosis indication, with a slightly smaller trial base than its older sibling teriparatide. It is a daily subcutaneous injectable prescription drug, not a dietary supplement. It raises bone density and cuts vertebral and nonvertebral fracture risk, but it carries a HISTORICAL rat-based osteosarcoma signal (the boxed warning and 2-year cumulative-use limit were REMOVED by the FDA in 2020-2021), causes hypercalcemia (less than teriparatide) and orthostatic dizziness, and must be obtained and supervised by a prescriber.
A pivotal phase-3 fracture RCT plus extension and three network meta-analyses show robust osteoporosis fracture reduction, but it rests on one fracture trial and carries hypercalcemia and a historical rat-osteosarcoma signal.
Abaloparatide (brand name Tymlos; development code BA058) is a synthetic 34-amino-acid analog of human parathyroid-hormone-related peptide, PTHrP(1-34).
It is an anabolic — bone-building — osteoporosis drug, one of only a small class of agents (alongside teriparatide and romosozumab) that stimulate new bone formation rather than merely slowing bone loss.
Mechanistically it selectively binds and activates the RG (transient-signaling) conformation of the parathyroid hormone type-1 (PTH1) receptor on osteoblasts; favoring the RG over the RØ conformation is thought to drive a more transient, formation-dominant signal that builds bone with proportionally less of the bone-resorbing response seen with PTH/teriparatide.
Critically — and unlike the grey-market 'research peptides' it is sometimes grouped with — abaloparatide is an FDA-approved prescription drug (approved April 2017) with a genuine pivotal trial.
The phase-3 ACTIVE RCT (JAMA 2016, n=2463 postmenopausal women) randomized to abaloparatide 80 µg/day, placebo, or open-label teriparatide for 18 months: new morphometric vertebral fractures fell ~86% and nonvertebral fractures fell significantly versus placebo, with larger bone-mineral-density (BMD) gains than placebo.
The ACTIVExtend study (JCEM 2018) showed that sequencing 24 months of alendronate after abaloparatide preserved and extended the benefit, with an 84% relative reduction in vertebral fracture over the full 43 months.
Head-to-head BMD data from ACTIVE found abaloparatide produced more BMD responders than teriparatide and better preserved cortical/forearm bone (numerically fewer wrist fractures). The ATOM trial (JBMR 2022, n=228 men) extended the indication to men, with large 12-month BMD gains.
Three network meta-analyses (BMJ 2023; ACP/Ann Intern Med 2023; Osteoporos Int 2025) consistently place abaloparatide and teriparatide as more effective than bisphosphonates for clinical and vertebral fractures, with the 2025 PTH1-agonist NMA suggesting abaloparatide has an edge over teriparatide for nonvertebral and hip fractures.
The honesty caveats: (1) the evidence base, while strong, rests on one pivotal fracture RCT plus extension and meta-analytic synthesis — fewer independent fracture trials than the longer-marketed teriparatide; (2) it is a prescription injectable, NOT a supplement, requiring a prescriber, daily subcutaneous self-injection, and periodic monitoring; (3) it carries a HISTORICAL osteosarcoma concern — chronic high-dose dosing in rats produced osteosarcomas comparably to PTH(1-34) (Regul Toxicol Pharmacol 2017), which underpinned an original boxed warning and a 2-year cumulative-use limit; the FDA REMOVED that boxed warning and the lifetime-duration limit in 2020-2021 after rat-specific mechanism data and clinical experience showed no human osteosarcoma signal, though it remains contraindicated where baseline osteosarcoma risk is increased (Paget's disease, prior skeletal radiation, unexplained elevated alkaline phosphatase, open epiphyses); (4) it causes dose-related hypercalcemia (though less than teriparatide) and orthostatic hypotension/dizziness, and raises uric acid; and (5) the anabolic effect is transient and treatment-dependent — benefit is consolidated by following the course with an antiresorptive.
Overall the evidence is Moderate-to-strong for osteoporosis fracture prevention in the approved populations, and essentially nonexistent for any off-label 'anti-aging' or general-bone use.
Abaloparatide is a synthetic PTHrP(1-34) analog that selectively binds and activates the RG (transient-signaling) conformation of the parathyroid hormone type-1 (PTH1) receptor. Favoring the RG over the RØ conformation produces a shorter, more transient receptor signal than PTH/teriparatide — thought to bias the response toward bone formation over resorption.
Intermittent (daily) PTH1-receptor stimulation activates osteoblasts and increases bone formation. In transiliac bone biopsies, 3 months of abaloparatide increased mineralizing surface and bone-formation rate on cancellous, endocortical, intracortical and periosteal surfaces, with a notable modeling-based (de novo) formation component.
How Abaloparatide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Approved regimen (Tymlos): 80 µg once daily by subcutaneous injection (abdomen), via a metered prefilled pen. This is a prescription drug — dose, duration and monitoring are set by a prescriber. The original 2-year cumulative-lifetime-use limit was REMOVED from the US label in 2021; duration is now an individualized clinical decision. There is no validated use outside osteoporosis fracture prevention.
Can be taken without food
| Form | Type |
|---|---|
| 💊Tymlos prefilled injector pen (prescription, via a clinician) | Recommended |
| 💊Teriparatide (Forteo) | Alternative |
| 💊Romosozumab (Evenity) | Alternative |
Abaloparatide is an FDA-approved prescription anabolic osteoporosis drug, not a dietary supplement. Teriparatide is the closely related PTH(1-34) analog with a longer track record; romosozumab is an anti-sclerostin antibody — both are alternative anabolic options chosen by a prescriber. Its approval does not transfer to grey-market peptides.
Compare Abaloparatide vs Teriparatide →Minimum: 18 months
Optimal: 18 months
Cycling: Not required
Note: Approved use is 80 µg subcutaneously once daily as directed by a prescriber, rotating abdominal injection sites; sit or lie down for the first doses in case of orthostatic dizziness. Not a self-optimized dietary supplement.
Dose-response data unavailable. The current published research for Abaloparatide does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
In the ACTIVE phase-3 RCT (n=2463 postmenopausal women), new morphometric vertebral fractures were markedly reduced (~86%) versus placebo over 18 months. ACTIVExtend showed an 84% relative reduction over the full 43 months when followed by alendronate. This is the best-evidenced effect and the basis for the approval.
Nonvertebral fracture risk was significantly lower with abaloparatide than placebo in ACTIVE. A 2025 PTH1-agonist network meta-analysis found abaloparatide had an advantage over teriparatide for nonvertebral fractures (OR ~0.87) and hip fractures (OR ~0.81).
BMD rose significantly at spine, hip and femoral neck. In the ATOM men's trial, 12-month lumbar-spine BMD rose ~8.5% vs ~1.2% with placebo. Head-to-head ACTIVE data showed more BMD responders than teriparatide and better-preserved forearm/cortical bone.
Like all anabolic agents, the effect is treatment-dependent and the course is time-limited; bone gains erode after stopping unless consolidated with an antiresorptive. ACTIVExtend showed that following abaloparatide with alendronate preserves and extends the fracture benefit.
As a PTH1-receptor agonist, abaloparatide can raise serum calcium — though less often than teriparatide (3.4% vs 6.4% in ACTIVE). Injection-site reactions, dizziness/orthostatic hypotension, palpitations, nausea and raised uric acid also occur. Monitoring is required and it is a prescriber-supervised drug.
Contraindicated. The historical rat osteosarcoma signal means abaloparatide is avoided where baseline bone-tumor risk is already elevated, even though the human boxed warning was removed.
Not for use in pregnancy or breastfeeding — abaloparatide treats postmenopausal/older-adult osteoporosis and developmental safety is not established.
Use only under medical supervision with calcium monitoring; abaloparatide can raise serum calcium, with implications for stone risk and digoxin toxicity.
Off-label and outside the evidence base. The trials were exclusively in osteoporosis at high fracture risk; benefit and safety in healthy users are unproven and it is a prescription injectable drug.
Abaloparatide can transiently raise serum calcium; because hypercalcemia predisposes to digoxin toxicity, patients on digoxin should be monitored carefully.
Abaloparatide can cause orthostatic hypotension and dizziness, typically within hours of a dose; additive effects with blood-pressure-lowering agents may worsen lightheadedness. Inject where the patient can sit or lie down.
Tip: Rotate abdominal injection sites; reactions are usually transient.
Tip: Take the first several doses sitting or lying down; rise slowly. Usually occurs within 4 hours of injection and resolves.
Tip: Often subsides over time; report persistent symptoms to the prescriber.
Tip: Monitor serum and urinary calcium; abaloparatide hypercalcemia was 3.4% vs 6.4% with teriparatide in ACTIVE. Caution in those prone to hypercalcemia or with active urolithiasis.
The commonly studied dose of Abaloparatide is Approved regimen (Tymlos): 80 µg once daily by subcutaneous injection (abdomen), via a metered prefilled pen. This is a prescription drug — dose, duration and monitoring are set by a prescriber. The original 2-year cumulative-lifetime-use limit was REMOVED from the US label in 2021; duration is now an individualized clinical decision. There is no validated use outside osteoporosis fracture prevention.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Abaloparatide — consistent daily use matters more than the time of day. The approved regimen is 80 µg subcutaneously once daily into the abdomen, rotating the injection site, independent of meals.
Abaloparatide should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are injection-site reactions (redness, pain, swelling, bruising), dizziness / orthostatic hypotension, palpitations, headache, nausea, fatigue, upper abdominal discomfort. Use caution if any of these apply to you: Conditions with increased baseline osteosarcoma risk — Paget's disease of bone, unexplained elevated alkaline phosphatase, prior external-beam or implant skeletal radiation, open epiphyses (pediatric/young-adult), or bone metastases / skeletal malignancy; Pre-existing hypercalcemia or conditions predisposing to hypercalcemia; Pregnancy and breastfeeding (not for use).
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
The anabolic signal translates into measurable BMD gains at the lumbar spine, total hip and femoral neck within months. In the ACTIVE trial BMD increases were significantly greater than placebo at all sites, and a greater proportion of patients reached BMD response thresholds than with teriparatide.
Anabolic osteoporosis agents are not combined; abaloparatide is used as a single anabolic course, then sequenced to an antiresorptive. Concurrent use is not supported by evidence.
Tip: Generally not clinically significant; relevant in gout or hyperuricemia — monitor if predisposed.